Bridgewater Wealth & Financial Management LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 10.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,363 shares of the biopharmaceutical company’s stock after buying an additional 3,577 shares during the quarter. Bridgewater Wealth & Financial Management LLC’s holdings in Pfizer were worth $1,255,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of PFE. Fisher Asset Management LLC increased its stake in shares of Pfizer by 3.9% during the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after buying an additional 1,275,832 shares during the period. Schwab Charles Investment Management Inc. grew its stake in Pfizer by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock valued at $1,117,696,000 after purchasing an additional 2,013,835 shares during the last quarter. Legal & General Group Plc boosted its holdings in Pfizer by 0.9% in the second quarter. Legal & General Group Plc now owns 31,463,283 shares of the biopharmaceutical company’s stock worth $1,056,857,000 after acquiring an additional 292,839 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after acquiring an additional 228,405 shares in the last quarter. Finally, Boston Partners boosted its holdings in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after acquiring an additional 1,649,801 shares in the last quarter. Institutional investors own 69.89% of the company’s stock.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by company insiders.
Pfizer Inc. (NYSE:PFE) traded down $0.06 on Thursday, reaching $35.50. The company had a trading volume of 15,807,773 shares, compared to its average volume of 19,960,639. Pfizer Inc. has a 1 year low of $30.51 and a 1 year high of $36.78. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market cap of $212,380.00, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the company earned $0.61 EPS. Pfizer’s revenue was up .9% on a year-over-year basis. research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.61%. Pfizer’s dividend payout ratio (DPR) is 79.01%.
PFE has been the subject of several recent analyst reports. Cowen set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Berenberg Bank reaffirmed a “hold” rating and set a $36.00 target price (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Jefferies Group reaffirmed a “hold” rating and set a $35.00 target price on shares of Pfizer in a report on Friday, August 18th. BMO Capital Markets restated a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research report on Wednesday, September 6th. Finally, Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $38.77.
ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/07/pfizer-inc-pfe-position-raised-by-bridgewater-wealth-financial-management-llc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.